The North America Kidney Cancer Diagnostics and Therapeutics Market was worth $1.25 billion in 2018 and estimated to be growing at a CAGR of 5.51%, to reach $1.63 billion by 2023. Though there has been extensive progress in science and technology to tackle cancer, it continues to threaten lives across the world.
Kidney cancer is one of the recurrent urologic tumours accounting for around 3% of all the human cancers. The occurrence rate of renal cell carcinoma has increased progressively in the recent decades.
The growth of the North America Kidney Cancer Diagnostics and Therapeutics Market is mainly driven by factors such as rising aging population, Changes in lifestyle such as increased intake of alcohol and disproportionate smoking, and government policies to provide better care for kidney Cancer. However, high treatment cost is one of the main factor hampering the growth of the market in this region.
The North America Kidney Cancer Diagnostics and Therapeutics market is segmented based on Type and Tests. The market for Kidney Cancer Diagnostics and Therapeutics, on the basis of Type is segmented into Transitional Cell Cancer, Renal cell carcinoma, Renal sarcoma, and Others. On the basis of Tests, the Kidney Cancer Diagnostics and Therapeutics market is segmented into Biopsy, CT Scan, Cystoscopy, Intravenous pyelogram, Kidney Ultrasound. Biopsy and CT Scan lead the tests segment in the Kidney Cancer Diagnostics and Therapeutics market accounting for more than 50% of the market.
The North America Kidney Cancer Diagnostics and Therapeutics market has been geographically segmented into segmented into US and Canada. The North America market is advanced and is focused on inventing cost-effective techniques. Companies are dedicated to research, sourcing, and quality, factors that are vital to the success of the industry.
The major companies dominating the Kidney Cancer Diagnostics and Therapeutics market in this region are GlaxoSmithKline, Bayer, Pfizer, Sanofi S.A, Hoffmann La Roche, Novartis, Abbott Laboratories.
1.Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Type
5.1.1 Transitional Cell Cancer
5.1.2 Renal cell carcinoma
5.1.3 Renal sarcoma
5.1.4 Other Cancers
5.2 By Tests
5.2.1 Biopsy
5.2.2 CT Scan
5.2.3 Cystoscopy
5.2.4 Intravenous pyelogram
5.2.5 Kidney Ultrasound
6. Geographical Analysis
6.1 Introduction
6.2 United States
6.3 Canada
7. Pipeline Product Analysis
7.1 Overview
7.2 Pipeline Development Landscape
7.3 Molecular Targets in the Pipeline
7.4 Clinical Trials
7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target
7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target
7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target.
8.Strategic Analysis
8.1 PESTLE analysis
8.1.1 Political
8.1.2 Economic
8.1.3 Social
8.1.4 Technological
8.1.5 Legal
8.1.6 Environmental
8.2 Porter’s Five analysis
8.2.1 Bargaining Power of Suppliers
8.2.2 Bargaining Power of Consumers
8.2.3 Threat of New Entrants
8.2.4 Threat of Substitute Products and Services
8.2.5 Competitive Rivalry within the Industry
9.Market Leaders' Analysis
9.1 GlaxoSmithKline
9.1.1 Overview
9.1.2 Product Analysis
9.1.3 Strategic Evaluation and Operations
9.1.4 Financial analysis
9.1.5 Legal issues
9.1.6 Recent Developments
9.1.7 SWOT analysis
9.1.8 Analyst View
9.2 Bayer
9.3 Pfizer
9.4 Sanofi S.A
9.5 Hoffmann La Roche
9.6 Novartis
9.7 Abbott Laboratories
10.Competitive Landscape
10.1 Market share analysis
10.2 Merger and Acquisition Analysis
10.3 Agreements, collaborations and Joint Ventures
10.4 New Product Launches
11.Expert Opinions
11.1 Market Outlook
11.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
